494 related articles for article (PubMed ID: 22645227)
1. Neuroendocrine tumor disease: an evolving landscape.
Frilling A; Akerström G; Falconi M; Pavel M; Ramos J; Kidd M; Modlin IM
Endocr Relat Cancer; 2012 Oct; 19(5):R163-85. PubMed ID: 22645227
[TBL] [Abstract][Full Text] [Related]
2. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
3. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
[TBL] [Abstract][Full Text] [Related]
4. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H
Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors.
Lindholm DP; Oberg K
Horm Metab Res; 2011 Nov; 43(12):832-7. PubMed ID: 22009449
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.
Singh S; Law C
Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):313-34. PubMed ID: 22646254
[TBL] [Abstract][Full Text] [Related]
7. Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.
Alexandraki KI; Kaltsas G
Endocrine; 2012 Feb; 41(1):40-52. PubMed ID: 22124940
[TBL] [Abstract][Full Text] [Related]
8. Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.
Zhang XB; Fan YB; Jing R; Getu MA; Chen WY; Zhang W; Dong HX; Dakal TC; Hayat A; Cai HJ; Ashrafizadeh M; Abd El-Aty AM; Hacimuftuoglu A; Liu P; Li TF; Sethi G; Ahn KS; Ertas YN; Chen MJ; Ji JS; Ma L; Gong P
Mil Med Res; 2024 Jun; 11(1):35. PubMed ID: 38835066
[TBL] [Abstract][Full Text] [Related]
9. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
Hofsli E
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
[TBL] [Abstract][Full Text] [Related]
10. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours.
Janson ET; Sørbye H; Welin S; Federspiel B; Grønbaek H; Hellman P; Mathisen O; Mortensen J; Sundin A; Thiis-Evensen E; Välimäki MJ; Oberg K; Knigge U
Acta Oncol; 2010 Aug; 49(6):740-56. PubMed ID: 20553100
[TBL] [Abstract][Full Text] [Related]
11. [Neuroendocrine tumours of pancreas and gastrointestinal tract].
Tsimmerman IaS
Klin Med (Mosk); 2009; 87(12):7-13. PubMed ID: 20135878
[TBL] [Abstract][Full Text] [Related]
12. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
13. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014.
Garcia-Carbonero R; JImenez-Fonseca P; Teulé A; Barriuso J; Sevilla I;
Clin Transl Oncol; 2014 Dec; 16(12):1025-34. PubMed ID: 25183048
[TBL] [Abstract][Full Text] [Related]
14. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
15. How should incidental NEN of the pancreas and gastrointestinal tract be followed?
Ariotti R; Partelli S; Muffatti F; Andreasi V; Della Sala F; Falconi M
Rev Endocr Metab Disord; 2018 Jun; 19(2):139-144. PubMed ID: 29527619
[TBL] [Abstract][Full Text] [Related]
16. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
[TBL] [Abstract][Full Text] [Related]
17. [New perspectives in diagnosis and therapy of endocrine gastroenteropancreatic (GEP) tumors with somatostatin analogues].
Rubello D; Rufini V; De Carlo E; Martini C; Calcagni ML; Sicolo N; Troncone L; Casara D
Minerva Endocrinol; 2003 Dec; 28(4):259-96. PubMed ID: 14752399
[TBL] [Abstract][Full Text] [Related]
18. Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system.
Delektorskaya VV; Kozlov NA; Chemeris GY
Klin Lab Diagn; 2013 Oct; (10):48-50, 10-3. PubMed ID: 24640093
[TBL] [Abstract][Full Text] [Related]
19. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
20. State of the art and future prospects in the management of neuroendocrine tumors.
Oberg K
Q J Nucl Med; 2000 Mar; 44(1):3-12. PubMed ID: 10932597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
